Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P06889 (Mol)
 630,302 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effect of estrogen structure on the conformation of the complex formed with estrogen receptor (ER) and the consensus estrogen response element (EREc) has been examined with gel mobility shift assay. Proteins in MCF-7 cell extracts formed three distinct complexes with ERE. Only the slowest moving complex contained ER as indicated by binding with anti-ER antibodies H222 and D547. This ER-ERE complex displayed increased electrophoretic mobility when formed in the presence of estradiol (E2) and bound radiolabeled 16 alpha-iodoestradiol. The antiestrogen ICI 164,384 decreased the mobility of the ER-ERE complex and blocked the effect of E2. The results reported here indicate that the position and location of hydroxyl groups on the estratriene nucleus is an important factor in determining the mobility of ER-EREc (or a variant ERE) in gel shift assays. The ability of E2 analogs to cause conformational changes detectable as altered mobility was not directly related either to their binding affinity for ER or to their ability to activate E2 responsive genes. Although several dihydroxyestrogens (estradiol-16 alpha, 1- and 2-hydroxyestratrien-17 beta-ol) caused an increase in the mobility of the ER-EREc, other ligands (estradiol-17 alpha, 4-hydroxyestratriene-17 beta-ol, 3-hydroxy estratriene, estratrien-17 beta-ol and 5-androsten-3 beta, 17 beta-diol) with a capacity for activating at least some E2 responsive genes in MCF-7 cells had little or no effect. On the basis of these and previously published results, it can be concluded that specific structure features of estrogens are responsible for conformational changes of ER-ERE complexes detectable in gel-shift assays. Furthermore, the identified structural characteristics of the ligand which are required for gel-shift are not the same as those previously reported to be essential for stimulation of transcriptional activity of ER.
J Steroid Biochem Mol Biol 1995 Sep
PMID:Relationship between estrogen structure and conformational changes in estrogen receptor/DNA complexes. 757 1

Clenbuterol (10-100 microM), a beta 2-adrenergic agonist, potentiated basal (unstimulated) and electrical stimulation-evoked release of 3H-norepinephrine from cerebral cortical slices in a concentration-dependent manner. The beta-adrenergic antagonists propranolol and ICI 118,551 did not antagonize the facilitatory effect of clenbuterol on basal 3H-norepinephrine efflux. Selective down-regulation of beta 2-adrenergic receptors produced by chronic administration of clenbuterol also did not alter this effect of in vitro clenbuterol, despite marked reductions in the density of these receptors. These results suggest that the increase in basal efflux of 3H-norepinephrine observed with clenbuterol was not mediated by beta 2-adrenergic receptors. The facilitatory effect of clenbuterol on basal 3H-norepinephrine efflux was Ca(2+)-independent, which may indicate an amphetamine-like mechanism of action. The enhanced basal efflux of 3H-norepinephrine produced by clenbuterol was stereoselective; there was a four-fold increase in basal 3H-norepinephrine efflux with the (+)-isomer of clenbuterol compared with that induced by the (-)-isomer; this contrasts with the stereoselectivity of the isomers for interacting with beta 2-adrenergic receptors. The present results may explain some of the behavioral actions of clenbuterol, particularly those observed after long-term treatment, and may be relevant to the antidepressant actions of this compound.
Res Commun Mol Pathol Pharmacol 1994 Dec
PMID:Clenbuterol increases norepinephrine release from rat brain slices by a calcium- and receptor-independent mechanism. 771 7

Growth of human breast cancer cells is controlled by multiple interacting factors that trigger different intracellular signaling pathways. The nonsteroidal antagonist 4-hydroxytamoxifen (OH-Tam), which acts as an antiestrogen, is also able to inhibit the mitogenic activity of epidermal growth factor (EGF) on hormone-responsive MCF7 cells. To further characterize the mechanism of this antigrowth factor activity, which is accompanied by an increase of high-affinity EGF binding and a drastic decrease in EGF receptor autophosphorylation, we studied the effect of OH-Tam on protein tyrosine phosphatase (PTPase) activity with specific in vitro assays using two different substrates. OH-Tam increased membrane PTPase activity in a time- and dose-dependent fashion whereas cytoplasmic enzyme activity remained unchanged. The increase in PTPase activity was mediated by the estrogen receptor (ER) since it was restricted to ER-positive cells, and the optimal OH-Tam concentration (ED50 = 1 nM) was correlated with the ligand affinity for ER. The increase in enzyme activity was selectively obtained with nuclear receptor ligands (OH-Tam, ICI 164,384) that inhibited growth factor-induced proliferation, whereas other inhibitors of estrogenic responses such as synthetic progestins and antiprogestins had no effect. The time course of stimulation (maximal stimulation at day 4) was concomitant to the loss of EGF mitogenic response. Moreover, addition of a specific PTPase inhibitor (5 microM sodium orthovanadate) to intact cells in culture prevented OH-Tam inhibition of cell proliferation, suggesting that these two events are closely associated.(ABSTRACT TRUNCATED AT 250 WORDS)
Mol Endocrinol 1994 Oct
PMID:Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells. 785 56

To better define the role of accessory protein as mediators of estrogen receptor (ER) function, we have used immuno-, steroid-, and site-specific DNA-affinity chromatography to identify and characterize proteins that associate with ER in extracts from ER-expressing Chinese hamster ovary (CHO-ER) cells. Two associated proteins [70 and 55 kilodaltons (kDa)] were observed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis silver stain analysis of all three column eluates. Two additional proteins (45 and 48 kDa) were preferentially retained by the ER-specific DNA affinity column. The 70-kDa protein was subsequently identified by Western blot analysis as a heat shock protein (hsp70). The 55-kDa protein was identified by N-terminal microsequencing as a member of the protein disulfide isomerase family. The 48- and 45-kDa proteins remain unidentified. To determine the possible differential effects of estrogen agonists and antagonists on human (h) ER interaction with these proteins, CHO-ER cells were labeled with [35S]methionine in the presence of estradiol, 4-hydroxytamoxifen (OH-Tam; partial agonist/antagonist), or ICI 182,780 (complete antagonist). None of these ligands altered the pattern of associated proteins when hER complexes were isolated by adsorption to the vitellogenin A2 estrogen response element (ERE). However, when hER was isolated by immunoadsorption, a reduction in the level of associated hsp70 was observed following treatment with estradiol or OH-Tam, compared to no treatment or treatment with ICI 182,780. By gel retardation analysis, maximal interaction of affinity-purified hER with ERE occurred in the presence of all four associated proteins. Removal of the 48- and 45-kDa proteins and/or hsp70 resulted in a decrease in hER/ERE association, which could be restored by the addition of purified hsp70 and/or a mixture of the 48- and 45-kDa proteins. The increased stability of the restored complex was due primarily to an increase in the association rate of hER with ERE. These results suggest that accessory proteins may be required for maximal ER interaction with EREs and that estrogens and estrogen antagonists may promote differential retention of hsp70 in the presence or absence of a specific ERE.
Mol Endocrinol 1994 Oct
PMID:The interaction of human estrogen receptor with DNA is modulated by receptor-associated proteins. 785 57

Recently we demonstrated that the effects of beta 2-adrenoceptor (AR) stimulation to augment Ca2+ current (ICa), cytosolic Ca2+ (Cai) transients, and contractility in rat ventricular myocytes are largely dissociated from its effect to increase cellular cAMP levels. This result suggested that beta 2ARs might be coupled to signaling pathways other than the Gs alpha-mediated activation of adenylyl cyclase. Here we show that pertussis toxin (PTX) pretreatment specifically potentiates the responses of rat heart cells to beta 2AR but not beta 1AR stimulation. After PTX pretreatment, 1) the dose-response curve for the effects of the beta 2AR agonist zinterol on contraction amplitude is shifted leftward and upward (EC50 changed from about 1.0 microM to 70 nM), 2) in indo-1-loaded cells, the maximal effects of zinterol (10(-5) M) on Cai transient and contraction amplitudes are additionally increased 1.7- and 2.0-fold, respectively, over those in control cells, and 3) the increase in ICa amplitude induced by the same zinterol concentration is potentiated by 2.5-fold. Similar effects of PTX are observed when beta 2ARs are stimulated by isoproterenol in the presence of a selective beta 1AR blocker, CGP 20712A. All effects of beta 2AR agonists in both PTX-treated and control cells are abolished by a selective beta 2AR blocker, ICI 118,551. In contrast, neither the base-line ICa, Cai transient, and contraction in the absence of beta AR stimulation nor the beta 1AR-mediated augmentations of these parameters are significantly altered by PTX treatment. These results demonstrate, for the first time, that the Gs-coupled beta 2AR can simultaneously activate a pathway that leads to functional inhibition in cardiac cells via a PTX-sensitive G protein. The activation of more than one G protein during beta 2AR stimulation, leading to functionally opposite effects, may provide a mechanism to protect the heart from Ca2+ overload and arrhythmias during the response to stress.
Mol Pharmacol 1995 Feb
PMID:Functional coupling of the beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. 787 40

beta-Adrenoreceptor has been studied in a clonal capillary endothelial cell line established from the vascular bed of the bovine adrenal medulla. [3H]Dihydroalprenolol ([3H]DHA) binding to the isolated plasma membranes from these cells has demonstrated the presence of beta-adrenoreceptors with two different affinities. The dissociation constants (Kd) have been found to be 0.27 +/- 0.09 x 10(-9) M and 2.96 +/- 0.31 x 10(-9) M, respectively with the corresponding Bmax of 5.1 +/- 0.05 and 70.0 +/- 0.2 pmol/mg protein, respectively. Inhibition of [3H]DHA binding to the beta-receptor by atenolol (a beta 1-antagonist) and ICI 118,551 (a beta 2-antagonist) has suggested that the IC50cor (= Ki) for atenolol and ICI 118,551 for high affinity site are 0.08 +/- 0.03 x 10(-12) M and 0.25 +/- 0.08 x 10(-12) M, respectively. This, therefore, indicates that both atenolol and ICI 118,551 are able to displace the bound ligand effectively but the beta 1-selective antagonist atenolol is 3 times more potent than its beta 2 counterpart, ICI 118,551. Displacement of [3H]DHA binding to the endothelial cell plasma membrane by the agonists isoproterenol, epinephrine and norepinephrine has established a relative order of Ki for these agents as isoproterenol (0.56 +/- 0.19 x 10(-9) M) < epinephrine (0.77 +/- 0.26(-9) M) > or = norepinephrine (0.71 +/- 0.24 x 10(-9) M) for the high affinity site. The corresponding values for the low affinity site, however, are 4.62 +/- 0.64 x 10(-9) M, 6.21 +/- 0.86 x 10(-9) M and 5.90 +/- 0.82 x 10(-9) M, respectively for the same agonists. Increased intracellular cAMP accompanied with cellular proliferation in the presence of isoproterenol has suggested not only the coupling of beta-adrenoreceptors to the adenylate cyclase system but also its involvement in endothelial cell proliferation.
Mol Cell Biochem 1994 Nov 09
PMID:Beta-adrenoreceptors of multiple affinities in a clonal capillary endothelial cell line and its functional implication. 787 97

The effects of desipramine, tranylcypromine, and phenelzine on beta-adrenoceptor subtype binding were measured in rat cerebral cortex and cerebellum. The drugs were administered to male Sprague Dawley rats for 28 d sc via 2ML4 Alzet osmotic minipumps (desipramine HCl 10, tranylcypromine HCl 1, phenelzine sulfate 5, 10 mg kg-1/d). Binding of [3H]CGP 12177 was measured to determine total beta-adrenoceptor density in each brain region. The relative densities of beta 1- and beta 2-adrenoceptors were directly calculated from competition analysis using ICI 89406 to displace [3H]CGP 12177. beta 1-Adrenoceptor density was decreased in cortical tissue following each antidepressant treatment, but no effects on beta 2-adrenoceptor density were evident. With cerebellar tissue, despite a higher density of beta 2-adrenoceptors in this area, no effects of antidepressants on beta 2-adrenoceptor density were evident. The present data confirm and extend previous reports of beta 1- but not beta 2-adrenoceptor downregulation in brain following chronic antidepressant drug treatment.
Mol Chem Neuropathol 1993 Sep
PMID:Effects of chronic antidepressant treatment on beta-adrenoceptor subtype binding in the rat cerebral cortex and cerebellum. 790 19

We studied the regulation of beta-adrenergic receptor (AR) subtypes co-existing in rat C6 glioma cells to clarify the importance of subtype ratio in responses to catecholamines. Radioligand binding studies with [125I]-cyanopindolol showed that beta 1- and beta 2-ARs co-existed in this cell line in approximately an 80:20 ratio. Norepinephrine (NE) and epinephrine (EPI) were equally potent in increasing cAMP accumulation, consistent with a primarily beta 1-response, although both beta 1- and beta 2-components of the response could be isolated using selective agonists (NE and zinterol), and antagonists (CGP 20712A and ICI 118,551). Little or no evidence of beta 3-ARs could be found in this cell line. Treatment of cells with 500 nM dexamethasone (DEX) for 48 hr increased the proportion of beta 2-ARs (20 to 60%). However, a reciprocal decrease in beta 1-ARs resulted in no change in total beta-ARs. Studies on the time-(12 to 72 hr) and concentration- (5 nM to 5000 nM) dependence of DEX treatment showed that increases in beta 2-ARs were closely linked to decreases in beta 1-ARs with little or no change in total receptor density observed at any time or in any concentration studied. Treatment with DEX also increased beta 2- and decreased beta 1-mediated cAMP responses, but did not alter the response to the nonselective agonist, isoproterenol. Northern blot analysis showed a 2- to 3-fold increase in beta 2-AR mRNA, but no change in beta 1-AR mRNA, after exposure to 50 or 500 nM DEX for 48 hr. Surprisingly, after DEX treatment, NE and EPI were still equally potent in activating cAMP accumulation, although responses to the beta 2-selective agonist, zinterol, were increased. These studies show a close reciprocal regulation by DEX of the relative proportions of beta 1- and beta 2-AR subtypes in C6 cells. The functional significance of the changing subtype ratios does not appear to be related to catecholamine responsiveness.
Mol Pharmacol 1993 Dec
PMID:Close reciprocal regulation of beta 1- and beta 2-adrenergic receptors by dexamethasone in C6 glioma cells: effects on catecholamine responsiveness. 790 14

With respect to the beta 1- and beta 2-adrenergic receptors (ARs), the beta 3-AR induces specific physiological effects in a few target tissues and exhibits atypical pharmacological properties that distinguish it unambiguously from its counterparts. Therefore, the beta 3-AR represents a suitable model to study the molecular mechanism responsible for receptor subtype selectivity and specificity. Potent beta 3-AR ligands newly characterized in Chinese hamster ovary cells expressing the beta 3-AR were also evaluated in Chinese hamster ovary cells expressing beta 1- and beta 2-ARs and were classified into three groups according to their pharmacological properties. Among the beta 1/beta 2/beta 3 agonists BRL 37344 and LY 79771 exhibit beta 3 selectivity in stimulating adenylyl cyclase; among the beta 1/beta 2 antagonists displaying beta 3 agonistic effects ICI 201651 exhibits beta 3-AR binding selectivity, whereas among the beta 1/beta 2/beta 3 antagonist class bupranolol is the most efficient (but not selective) beta 3-AR antagonist. The structures of these ligands were simulated and compared using computer-generated molecular modeling. Structure-activity relationship analysis indicates that potent or selective beta 3-AR compounds, in addition to possessing a pharmacophore common to all beta-AR ligands, contain a long and bulky alkylamine substituent moiety, which is able to adopt and exchange extended and stacked conformations. Computerized three-dimensional models of the beta 1-, beta 2-, and beta 3-AR binding sites show that more bulky amino acid side chains point inside the groove of the beta 1 and beta 2 sites, compared with the beta 3 site, in a region implicated in signal processing. The long alkylamine chain of compounds behaving as beta 1/beta 2 antagonists and beta 3 agonists may thus adopt either a stacked conformation in the encumbered beta 1- and beta 2-AR sites, leading to antagonistic effects, or an extended conformation in the less encumbered beta 3 site, thus interacting with specific residues implicated in signal transduction.
Mol Pharmacol 1993 Dec
PMID:Structural and conformational features determining selective signal transduction in the beta 3-adrenergic receptor. 790 15

We have produced a fine restriction map around the locus D4F104S1 (previously designated D4S810); a probe to this locus, p13E-11, identifies a polymorphic EcoRI fragment containing 3.2kb tandem repeats and detects DNA rearrangements associated with facioscapulohumeral muscular dystrophy (FSHD). We developed an STS (D4F106S1) which maps 2kb proximal to D4F104S1, and used this to isolate a 470kb YAC (y25C2E) from the ICI YAC library and a 930kb YAC (y956A11) from the CEPH megabase library. Both YACs contain the loci D4S139, D4F35S1 and D4F104S1. A cosmid library was produced from YAC y25C2E and two cosmid contigs constructed; a 115kb contig encompassing D4S139, and one of 135kb linking D4F35S1 and D4F104S1 and extending distal to the EcoRI fragment detected by p13E-11. A fine restriction map of both these contigs has been generated, allowing the orientation of the EcoRI fragment rearranged in FSHD to be determined. YAC y956A11 was used to confirm the integrity of y25C2E and the map of this region. 9B6A, a probe to the homeobox region of the tandem repeat D4Z4, identified a cross-hybridising sequence proximal to D4F104S1, however, p13E-11 does not detect this additional locus. CpG islands were identified between D4S139 and D4F35S1 and within each copy of the tandem repeat. The probe 9B6A detected each copy of the repeat motif, suggesting there is homeobox present in every copy of the 3.2kb repeat.
Hum Mol Genet 1993 Oct
PMID:Fine mapping of the FSHD gene region orientates the rearranged fragment detected by the probe p13E-11. 790 81


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>